Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Section of Pharmacology and Toxicology, Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Viale G. Pieraccini, 6, 50139, Florence, Italy.
Eur J Clin Pharmacol. 2022 Sep;78(9):1511-1519. doi: 10.1007/s00228-022-03354-7. Epub 2022 Jun 22.
Benzodiazepines (BZD), Z-drugs (ZD), and opioids share a high risk of abuse. This study assessed and characterised adverse events (AEs) related to BDZ, ZD, and opioids leading to emergency department (ED) visits in the Italian setting.
ED accesses related to BDZ, ZD, and/or opioids were analysed from the MEREAFaPS database. Information on AEs, suspected and concomitant medications was retrieved. Multivariate logistic regression was used to estimate the reporting odds ratios (RORs) of hospitalisation according to the different treatments.
A total of 5,970 pharmacovigilance reports involving BZD/ZD (n = 3,106), opioids (n = 2,767), or their combination (n = 97) were analysed. Compared to opioids, patients with BZD/ZD-related AEs were often younger (51 vs 64 years), more frequently presented 2+ suspected medications (13 vs 3%), and often had a history of abuse (4%). Twenty-three percent of BZD/ZD-related AEs were related to drug abuse (vs 2% of opioid-related ones) and frequently required patient hospitalisation (52% vs 24%), despite the significantly lower clinical complexity of these patients as compared to those on opioids. An increased risk of hospitalisation was found for flurazepam (ROR 1.62; 95% CI, 1.18-2.22), prazepam (2.66; 1.05-6.70), lorazepam (1.26; 1.07-1.49), and morphine (1.76; 1.11-2.79).
These results indicate that, in Italy, the inappropriate use of BZD/ZD is a relevant heath issue, often leading to serious AEs requiring patients' ED visits and hospitalisation, especially in young women and patients with a history of substance abuse.
苯二氮䓬类药物(BZD)、Z 类药物(ZD)和阿片类药物滥用风险高。本研究评估并描述了 BZD、ZD 和阿片类药物导致意大利急诊就诊的不良事件(AE)。
从 MEREAFaPS 数据库中分析了与 BZD、ZD 和/或阿片类药物相关的 ED 就诊情况。检索了 AE、可疑和伴随药物的信息。采用多变量逻辑回归估计了不同治疗方法的住院报告比值比(ROR)。
共分析了 5970 例涉及 BZD/ZD(n=3106)、阿片类药物(n=2767)或两者组合(n=97)的药物警戒报告。与阿片类药物相比,BZD/ZD 相关 AE 患者通常更年轻(51 岁 vs 64 岁),更常出现 2 种以上可疑药物(13% vs 3%),且常有滥用史(4%)。BZD/ZD 相关 AE 中有 23%与药物滥用有关(阿片类药物相关 AE 为 2%),且经常需要住院治疗(52% vs 24%),尽管这些患者的临床复杂性明显低于阿片类药物患者。氟西泮(ROR 1.62;95%CI,1.18-2.22)、地西泮(2.66;1.05-6.70)、劳拉西泮(1.26;1.07-1.49)和吗啡(1.76;1.11-2.79)的住院风险增加。
这些结果表明,在意大利,BZD/ZD 的不当使用是一个重要的健康问题,经常导致严重的 AE,需要患者到 ED 就诊和住院治疗,尤其是在年轻女性和有药物滥用史的患者中。